ProfileGDS4814 / ILMN_2294878
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 72% 70% 72% 72% 73% 75% 71% 72% 71% 71% 72% 72% 71% 70% 72% 72% 71% 71% 71% 69% 71% 72% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)83.430872
GSM780708Untreated after 4 days (C2_1)72.926370
GSM780709Untreated after 4 days (C3_1)80.952272
GSM780719Untreated after 4 days (C1_2)83.274972
GSM780720Untreated after 4 days (C2_2)85.99873
GSM780721Untreated after 4 days (C3_2)96.372575
GSM780710Trastuzumab treated after 4 days (T1_1)77.662871
GSM780711Trastuzumab treated after 4 days (T2_1)81.049172
GSM780712Trastuzumab treated after 4 days (T3_1)78.275171
GSM780722Trastuzumab treated after 4 days (T1_2)76.217871
GSM780723Trastuzumab treated after 4 days (T2_2)79.329372
GSM780724Trastuzumab treated after 4 days (T3_2)81.447872
GSM780713Pertuzumab treated after 4 days (P1_1)75.782271
GSM780714Pertuzumab treated after 4 days (P2_1)71.634970
GSM780715Pertuzumab treated after 4 days (P3_1)79.903172
GSM780725Pertuzumab treated after 4 days (P1_2)82.067272
GSM780726Pertuzumab treated after 4 days (P2_2)78.21271
GSM780727Pertuzumab treated after 4 days (P3_2)76.899271
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)78.307771
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)69.005769
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)78.770871
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)82.478772
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)78.165171